Charles River Laboratories International, Inc. Stock
Equities
CRL
US1598641074
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
224.8 USD | -3.36% | -2.32% | -4.93% |
Financials (USD)
Sales 2024 * | 4.22B | Sales 2025 * | 4.53B | Capitalization | 11.98B |
---|---|---|---|---|---|
Net income 2024 * | 406M | Net income 2025 * | 513M | EV / Sales 2024 * | 3.3 x |
Net Debt 2024 * | 1.94B | Net Debt 2025 * | 1.46B | EV / Sales 2025 * | 2.97 x |
P/E ratio 2024 * |
28.4
x | P/E ratio 2025 * |
23
x | Employees | 21,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.11% |
Latest transcript on Charles River Laboratories International, Inc.
1 day | -3.36% | ||
1 week | -4.48% | ||
Current month | -1.86% | ||
1 month | -4.74% | ||
3 months | -8.41% | ||
6 months | +19.82% | ||
Current year | -4.93% |
Managers | Title | Age | Since |
---|---|---|---|
James Foster
CEO | Chief Executive Officer | 73 | 75-12-31 |
Flavia Pease
DFI | Director of Finance/CFO | 51 | 22-04-24 |
Birgit Girshick
COO | Chief Operating Officer | 54 | 89-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
George Massaro
BRD | Director/Board Member | 76 | 02-12-31 |
Virginia Wilson
BRD | Director/Board Member | 68 | 19-09-30 |
Robert Bertolini
BRD | Director/Board Member | 61 | 11-01-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.05% | 1 M€ | +0.15% | - | |
2.07% | 5 M€ | -1.80% | - | |
1.08% | 0 M€ | 0.00% | - | |
0.98% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 224.8 | -3.36% | 1,301,402 |
24-05-15 | 232.6 | -0.11% | 529,498 |
24-05-14 | 232.8 | +1.93% | 502,307 |
24-05-13 | 228.4 | +0.13% | 447,273 |
24-05-10 | 228.1 | -0.86% | 842,499 |
Delayed Quote Nyse, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.93% | 11.98B | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- CRL Stock